These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20846522)

  • 41. Steatosis DeLIVERs high-sensitivity C-reactive protein.
    Luyendyk JP; Guo GL
    Arterioscler Thromb Vasc Biol; 2011 Aug; 31(8):1714-5. PubMed ID: 21775769
    [No Abstract]   [Full Text] [Related]  

  • 42. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
    Targher G; Marra F; Marchesini G
    Diabetologia; 2008 Nov; 51(11):1947-53. PubMed ID: 18762907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk.
    Musso G
    Ann Med; 2011; 43(6):413-7. PubMed ID: 21604916
    [No Abstract]   [Full Text] [Related]  

  • 44. Age as a modifiable risk factor for cardiovascular disease.
    Sniderman AD; Furberg CD
    Lancet; 2008 May; 371(9623):1547-9. PubMed ID: 18321568
    [No Abstract]   [Full Text] [Related]  

  • 45. Nonalcoholic fatty liver disease is a potential risk factor for cardiovascular diseases.
    Tao H; Shi KH; Wu JX; Zhan HY
    Nutr Metab Cardiovasc Dis; 2014 Mar; 24(3):e11-2. PubMed ID: 24444807
    [No Abstract]   [Full Text] [Related]  

  • 46. Nonalcoholic fatty liver disease and cardiovascular risk: is there a place for obstructive sleep apnea?
    Mirrakhimov AE; Mirrakhimov EM
    Can J Cardiol; 2013 Sep; 29(9):1139.e7. PubMed ID: 23265092
    [No Abstract]   [Full Text] [Related]  

  • 47. Reply to Mirrakhimov and Mirrakhimov--nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents.
    Alp H
    Can J Cardiol; 2013 Sep; 29(9):1139.e9. PubMed ID: 23352427
    [No Abstract]   [Full Text] [Related]  

  • 48. Abnormal liver function tests and metabolic syndrome--is fatty liver related to risks for atherosclerosis beyond obesity?
    Sakurai M; Takamura T; Miura K; Kaneko S; Nakagawa H
    Intern Med; 2009; 48(18):1573-4. PubMed ID: 19755756
    [No Abstract]   [Full Text] [Related]  

  • 49. [Association between non-alcoholic fatty liver disease and atherosclerosis].
    He Q; He B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):571-3. PubMed ID: 21033144
    [No Abstract]   [Full Text] [Related]  

  • 50. C reactive protein levels in non-alcoholic fatty liver disease.
    Dogru T; Genc H; Bagci S
    J Hepatol; 2012 Feb; 56(2):507-8; author reply 508-10. PubMed ID: 21888877
    [No Abstract]   [Full Text] [Related]  

  • 51. [The pathophysiological role of gut in non-alcoholic fatty liver disease].
    Liu YL; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2011 Sep; 19(9):651-2. PubMed ID: 22152377
    [No Abstract]   [Full Text] [Related]  

  • 52. Teasing out the value of new C-reactive protein test.
    Sandrick K
    CAP Today; 2000 Jan; 14(1):43-6. PubMed ID: 10788292
    [No Abstract]   [Full Text] [Related]  

  • 53. C-reactive protein and cardiovascular disease: differences between humans and mice.
    Jeppesen J; Asferg C
    Hypertension; 2010 Jul; 56(1):e15; author reply e16. PubMed ID: 20479326
    [No Abstract]   [Full Text] [Related]  

  • 54. THE INFLUENCE OF PLACENTAL DRUG LAENNEC ON MOTOR FUNCTION OF THE BILIARY TRACT IN PATIENTS WITH FATTY DEGENERATION OF LIVER.
    Maksimov VA; Buntin ES; Buntina BG; Mysenkova EE; Samartsev KN; Vostokovf GV; Burdenko NN
    Eksp Klin Gastroenterol; 2016; (11):100-103. PubMed ID: 29889453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
    Rowe IA; Allen AM
    Hepatology; 2023 Jun; 77(6):1843-1845. PubMed ID: 36738088
    [No Abstract]   [Full Text] [Related]  

  • 56. The association between fatty liver disease and blood pressure in a population-based cohort study.
    Lau K; Lorbeer R; Haring R; Schmidt CO; Wallaschofski H; Nauck M; John U; Baumeister SE; Völzke H
    J Hypertens; 2012 Jun; 30(6):1260-1. PubMed ID: 22573082
    [No Abstract]   [Full Text] [Related]  

  • 57. Laboratory variability and precise clinical decision making.
    Redberg RF
    Arch Intern Med; 2012 Oct; 172(19):1521. PubMed ID: 22945553
    [No Abstract]   [Full Text] [Related]  

  • 58. Preanalytic conditions of the C-reactive protein are of paramount importance to use as a predictor of cardiovascular disease in clinical practice.
    Dominguez-Rodriguez A; Abreu-Gonzalez P
    Int J Cardiol; 2012 Jul; 158(3):467. PubMed ID: 22633780
    [No Abstract]   [Full Text] [Related]  

  • 59. Re: "Tracking of cardiovascular risk factors: the Tromsø Study, 1979, 1995".
    Wang Y; Wang X
    Am J Epidemiol; 2002 Jun; 155(12):1144-5; author reply 1145. PubMed ID: 12048230
    [No Abstract]   [Full Text] [Related]  

  • 60. Endotoxin Inflammatory Action on Cells by Dysregulated-Immunological-Barrier-Linked ROS-Apoptosis Mechanisms in Gut-Liver Axis.
    Dumitru A; Matei E; Cozaru GC; Chisoi A; Alexandrescu L; Popescu RC; Butcaru MP; Dumitru E; Rugină S; Tocia C
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.